Oral HIV‐associated Kaposi sarcoma
Identifieur interne : 003A98 ( Main/Exploration ); précédent : 003A97; suivant : 003A99Oral HIV‐associated Kaposi sarcoma
Auteurs : L. Pantanowitz [États-Unis] ; R. A. G. Khammissa [Afrique du Sud] ; J. Lemmer [Afrique du Sud] ; L. Feller [Afrique du Sud]Source :
- Journal of Oral Pathology & Medicine [ 0904-2512 ] ; 2013-03.
Descripteurs français
- KwdFr :
- Antirétroviraux (usage thérapeutique), Herpèsvirus humain de type 8 (physiologie), Humains, Infections opportunistes liées au SIDA (anatomopathologie), Infections opportunistes liées au SIDA (traitement médicamenteux), Infections à VIH (anatomopathologie), Lymphoedème (anatomopathologie), Sarcome de Kaposi (anatomopathologie), Sarcome de Kaposi (traitement médicamenteux), Thérapie antirétrovirale hautement active, Tumeurs de la bouche (anatomopathologie), Tumeurs de la bouche (traitement médicamenteux).
- MESH :
- anatomopathologie : Infections opportunistes liées au SIDA, Infections à VIH, Lymphoedème, Sarcome de Kaposi, Tumeurs de la bouche.
- physiologie : Herpèsvirus humain de type 8.
- traitement médicamenteux : Infections opportunistes liées au SIDA, Sarcome de Kaposi, Tumeurs de la bouche.
- usage thérapeutique : Antirétroviraux.
- Humains, Thérapie antirétrovirale hautement active.
English descriptors
- KwdEn :
- AIDS-Related Opportunistic Infections (drug therapy), AIDS-Related Opportunistic Infections (pathology), Anti-Retroviral Agents (therapeutic use), Antiretroviral Therapy, Highly Active, HIV Infections (pathology), Herpesvirus 8, Human (physiology), Humans, Lymphedema (pathology), Mouth Neoplasms (drug therapy), Mouth Neoplasms (pathology), Sarcoma, Kaposi (drug therapy), Sarcoma, Kaposi (pathology).
- MESH :
- chemical , therapeutic use : Anti-Retroviral Agents.
- drug therapy : AIDS-Related Opportunistic Infections, Mouth Neoplasms, Sarcoma, Kaposi.
- pathology : AIDS-Related Opportunistic Infections, HIV Infections, Lymphedema, Mouth Neoplasms, Sarcoma, Kaposi.
- physiology : Herpesvirus 8, Human.
- Antiretroviral Therapy, Highly Active, Humans.
Abstract
J Oral Pathol Med (2012) Kaposi sarcoma (KS), an AIDS defining condition, remains one of the most commonly HIV‐associated neoplasms. While the use of highly active antiretroviral therapy (HAART) has brought about a dramatic decrease in the prevalence and incidence of AIDS‐KS worldwide, this has not been the case in resource‐poor sub‐Saharan African countries, where HIV has reached epidemic proportions and human herpesvirus‐8 infection is endemic. Oral involvement is a common manifestation of AIDS‐associated KS and may be an early presenting finding of HIV infection. The clinical manifestation of oral KS can vary and may have an unpredictable course ranging from mild to fulminant. Rapidly progressive facial lymphoedema associated with extensive advanced oral KS portends a poor prognosis. Oral KS may regress with antiretroviral therapy or may flare up as part of the immune reconstitution inflammatory syndrome. The oral lesions of AIDS‐KS are best managed with HAART together with systemic chemotherapy. This article provides a review of contemporary knowledge of the biology, pathology, clinical features and management of oral AIDS‐KS.
Url:
DOI: 10.1111/j.1600-0714.2012.01180.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 004B52
- to stream Istex, to step Curation: 004B52
- to stream Istex, to step Checkpoint: 000126
- to stream PubMed, to step Corpus: 002097
- to stream PubMed, to step Curation: 002097
- to stream PubMed, to step Checkpoint: 002097
- to stream Ncbi, to step Merge: 004E34
- to stream Ncbi, to step Curation: 004E34
- to stream Ncbi, to step Checkpoint: 004E34
- to stream Main, to step Merge: 003B07
- to stream Main, to step Curation: 003A98
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral HIV‐associated Kaposi sarcoma</title><author><name sortKey="Pantanowitz, L" sort="Pantanowitz, L" uniqKey="Pantanowitz L" first="L." last="Pantanowitz">L. Pantanowitz</name></author><author><name sortKey="Khammissa, R A G" sort="Khammissa, R A G" uniqKey="Khammissa R" first="R. A. G." last="Khammissa">R. A. G. Khammissa</name></author><author><name sortKey="Lemmer, J" sort="Lemmer, J" uniqKey="Lemmer J" first="J." last="Lemmer">J. Lemmer</name></author><author><name sortKey="Feller, L" sort="Feller, L" uniqKey="Feller L" first="L." last="Feller">L. Feller</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A0A410A55407612407B53F47C4868210C88AB512</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/j.1600-0714.2012.01180.x</idno><idno type="url">https://api.istex.fr/document/A0A410A55407612407B53F47C4868210C88AB512/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">004B52</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004B52</idno><idno type="wicri:Area/Istex/Curation">004B52</idno><idno type="wicri:Area/Istex/Checkpoint">000126</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000126</idno><idno type="wicri:doubleKey">0904-2512:2013:Pantanowitz L:oral:hiv:associated</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:22672182</idno><idno type="wicri:Area/PubMed/Corpus">002097</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002097</idno><idno type="wicri:Area/PubMed/Curation">002097</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002097</idno><idno type="wicri:Area/PubMed/Checkpoint">002097</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002097</idno><idno type="wicri:Area/Ncbi/Merge">004E34</idno><idno type="wicri:Area/Ncbi/Curation">004E34</idno><idno type="wicri:Area/Ncbi/Checkpoint">004E34</idno><idno type="wicri:Area/Main/Merge">003B07</idno><idno type="wicri:Area/Main/Curation">003A98</idno><idno type="wicri:Area/Main/Exploration">003A98</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Oral HIV‐associated Kaposi sarcoma</title><author><name sortKey="Pantanowitz, L" sort="Pantanowitz, L" uniqKey="Pantanowitz L" first="L." last="Pantanowitz">L. Pantanowitz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Khammissa, R A G" sort="Khammissa, R A G" uniqKey="Khammissa R" first="R. A. G." last="Khammissa">R. A. G. Khammissa</name><affiliation wicri:level="1"><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Department of Periodontology and Oral Medicine, School of Dentistry, University of Limpopo, Medunsa</wicri:regionArea><wicri:noRegion>Medunsa</wicri:noRegion></affiliation></author><author><name sortKey="Lemmer, J" sort="Lemmer, J" uniqKey="Lemmer J" first="J." last="Lemmer">J. Lemmer</name><affiliation wicri:level="1"><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Department of Periodontology and Oral Medicine, School of Dentistry, University of Limpopo, Medunsa</wicri:regionArea><wicri:noRegion>Medunsa</wicri:noRegion></affiliation></author><author><name sortKey="Feller, L" sort="Feller, L" uniqKey="Feller L" first="L." last="Feller">L. Feller</name><affiliation wicri:level="1"><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Department of Periodontology and Oral Medicine, School of Dentistry, University of Limpopo, Medunsa</wicri:regionArea><wicri:noRegion>Medunsa</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Oral Pathology & Medicine</title><title level="j" type="alt">JOURNAL ORAL PATHOLOGY MEDICINE</title><idno type="ISSN">0904-2512</idno><idno type="eISSN">1600-0714</idno><imprint><biblScope unit="vol">42</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="201">201</biblScope><biblScope unit="page" to="207">207</biblScope><biblScope unit="page-count">7</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2013-03">2013-03</date></imprint><idno type="ISSN">0904-2512</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0904-2512</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS-Related Opportunistic Infections (drug therapy)</term><term>AIDS-Related Opportunistic Infections (pathology)</term><term>Anti-Retroviral Agents (therapeutic use)</term><term>Antiretroviral Therapy, Highly Active</term><term>HIV Infections (pathology)</term><term>Herpesvirus 8, Human (physiology)</term><term>Humans</term><term>Lymphedema (pathology)</term><term>Mouth Neoplasms (drug therapy)</term><term>Mouth Neoplasms (pathology)</term><term>Sarcoma, Kaposi (drug therapy)</term><term>Sarcoma, Kaposi (pathology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antirétroviraux (usage thérapeutique)</term><term>Herpèsvirus humain de type 8 (physiologie)</term><term>Humains</term><term>Infections opportunistes liées au SIDA (anatomopathologie)</term><term>Infections opportunistes liées au SIDA (traitement médicamenteux)</term><term>Infections à VIH (anatomopathologie)</term><term>Lymphoedème (anatomopathologie)</term><term>Sarcome de Kaposi (anatomopathologie)</term><term>Sarcome de Kaposi (traitement médicamenteux)</term><term>Thérapie antirétrovirale hautement active</term><term>Tumeurs de la bouche (anatomopathologie)</term><term>Tumeurs de la bouche (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Retroviral Agents</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections opportunistes liées au SIDA</term><term>Infections à VIH</term><term>Lymphoedème</term><term>Sarcome de Kaposi</term><term>Tumeurs de la bouche</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>Mouth Neoplasms</term><term>Sarcoma, Kaposi</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>HIV Infections</term><term>Lymphedema</term><term>Mouth Neoplasms</term><term>Sarcoma, Kaposi</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Herpèsvirus humain de type 8</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Herpesvirus 8, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections opportunistes liées au SIDA</term><term>Sarcome de Kaposi</term><term>Tumeurs de la bouche</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirétroviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Thérapie antirétrovirale hautement active</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">J Oral Pathol Med (2012) Kaposi sarcoma (KS), an AIDS defining condition, remains one of the most commonly HIV‐associated neoplasms. While the use of highly active antiretroviral therapy (HAART) has brought about a dramatic decrease in the prevalence and incidence of AIDS‐KS worldwide, this has not been the case in resource‐poor sub‐Saharan African countries, where HIV has reached epidemic proportions and human herpesvirus‐8 infection is endemic. Oral involvement is a common manifestation of AIDS‐associated KS and may be an early presenting finding of HIV infection. The clinical manifestation of oral KS can vary and may have an unpredictable course ranging from mild to fulminant. Rapidly progressive facial lymphoedema associated with extensive advanced oral KS portends a poor prognosis. Oral KS may regress with antiretroviral therapy or may flare up as part of the immune reconstitution inflammatory syndrome. The oral lesions of AIDS‐KS are best managed with HAART together with systemic chemotherapy. This article provides a review of contemporary knowledge of the biology, pathology, clinical features and management of oral AIDS‐KS.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Pantanowitz, L" sort="Pantanowitz, L" uniqKey="Pantanowitz L" first="L." last="Pantanowitz">L. Pantanowitz</name></region></country><country name="Afrique du Sud"><noRegion><name sortKey="Khammissa, R A G" sort="Khammissa, R A G" uniqKey="Khammissa R" first="R. A. G." last="Khammissa">R. A. G. Khammissa</name></noRegion><name sortKey="Feller, L" sort="Feller, L" uniqKey="Feller L" first="L." last="Feller">L. Feller</name><name sortKey="Lemmer, J" sort="Lemmer, J" uniqKey="Lemmer J" first="J." last="Lemmer">J. Lemmer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A98 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A98 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A0A410A55407612407B53F47C4868210C88AB512
|texte= Oral HIV‐associated Kaposi sarcoma
}}
| This area was generated with Dilib version V0.6.31. |  |